Pharyngitis Market Insights

About Report

Global pharyngitis market is projected to bring in US$ 1,679.0 million revenue by 2026 end. Pharyngitis market size is expected to record a CAGR of 3.4% during the forecast period, 2017-2026.

Pharyngitis commonly known as a sore throat is caused by viral or bacterial infection. The most common bacteria infecting throat is Group A streptococcus. Various clinical trials are being carried on to find the best formulation effective in treating sore throat.

There is also a focus on patients receiving medication as per the clinical needs and also meet their individual requirement. The healthcare industry across the globe is also emphasizing on appropriate diagnosis, drug selection, dosage, drug delivery route, duration of administration, proper follow-up, and correct information on possible side-effects.

The latest study by Fact.MR expects the global market for pharyngitis to experience sluggish growth. Pharyngitis is the most common manifestation of infection.

Antibiotics are given in case of a sore throat, however, they provide very modest benefit. It is still unclear which antibiotic is the best for the treatment of a sore throat. Hence, various research and trials are being conducted to find most effective antibiotic.

Beta Lactams to Emerge as the Most-Preferred Drug Class

Compared to the various drug class, beta lactams is likely to emerge as one of the most preferred drug class between 2017 and 2026. Beta lactams is projected to bring in nearly US$ 500 million revenue by 2026 end.

Beta-lactams include cephalosporins and penicillins. These drugs are active against many harmful organisms. Moreover, the recent development of broad-spectrum beta-lactams antibiotics active against gram-negative organisms has increased their use.

Retail Pharmacies and Drug Stores to Emerge as the Biggest Distribution Channel

Retail pharmacies and drug stores are likely to gain maximum revenue share. By 2026 end, retail pharmacies and drug stores are projected to bring in nearly US$ 700 million revenue.

A sore throat is very common, pharmacists can assess specific symptoms as described by patients and based on it can suggest Over the Counter (OTC) drug that available at retail pharmacies and drug stores. One of the most commonly used OTC products for treating sore throat is lozenges. Moreover, pharmaceutical companies are also introducing new products that can offer rapid relief in pain.

Oral Drug Delivery to Gain Maximum Traction between 2017 and 2026

Oral drug delivery is likely to emerge as the most-preferred drug administration route. Oral drug delivery is projected to create an incremental opportunity of over US$ 300 million between 2017 and 2026. Owing to the cost-effectiveness, convenience and high patient compliance, oral drug delivery is witnessing significant growth.

However, many drugs are poorly bioavailable when administered. Hence, lipid-based drug delivery system is one of the emerging trends addressing bioavailability challenges. Moreover, oral drug delivery is the least invasive method as compared to other routes. Targeted drug delivery is also an emerging trend, in which the drug is active only in the targeted area.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global pharyngitis market through 2026, which include

• Pfizer Inc.
• GlaxoSmithKline PLC
• Novartis AG
• BioStar Pharmaceuticals Inc.
• Zambon Group SpA.

Market Taxonomy

Drug Class	Beta Lactams Macrolides Cephalosporins Fluoroquinolones Tetracycline Other Products
Distribution Channel	Hospital Pharmacies Retail Pharmacies and Drug Stores Online Pharmacies
Mode of Delivery	Oral Intravenous Intramuscular Other Mode of Delivery

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)